SRPT · Sarepta Therapeutics
AI read · Neutral
The AI's read
The higher targets from J.P. Morgan and Deutsche Bank point to more room for Sarepta's share price. But all three firms rate Sarepta at hold, so their views do not show strong confidence in a rise.